SCHEMBL3524384

SCHEMBL3524384

COC(=O)CCc1cc2cc(F)c(Cl)cc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MTNR1A P48039 4/20 0.38
MTNR1B P49286 3/20 0.38
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GAA P10253 1/20 0.36
ATP6AP1 Q15904 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
SRC P12931 1/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
S1PR1 P21453 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527645 0.89 EGFR (0.44) EGFRSMN1; SMN2MTNR1AMTNR1BKDM4E
SCHEMBL22077219 0.83 MTNR1A (0.39) EGFRSMN1; SMN2MTNR1AMTNR1BKDM4E
SCHEMBL22074489 0.82 EGFR (0.41) EGFRSMN1; SMN2MTNR1AMTNR1BKDM4E
SCHEMBL3525308 0.78 MTNR1A (0.48) EGFRSMN1; SMN2MTNR1AMTNR1BKDM4E
SCHEMBL27713368 0.76 ALDH1A1 (0.35) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL22074488 0.74 MTNR1A (0.35) EGFRSMN1; SMN2MTNR1AMTNR1BKDM4E
SCHEMBL852679 0.74 BACE1 (0.49) EGFRSMN1; SMN2MTNR1AMTNR1BKDM4E
SCHEMBL16240166 0.74 MTNR1A (0.49) EGFRSMN1; SMN2MTNR1AMTNR1BKDM4E
SCHEMBL1307049 0.73 ALPL (0.52) SMN1; SMN2KDM4EALDH1A1HPGDGAA
SCHEMBL30310681 0.73 ALPL (0.52) SMN1; SMN2KDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP EGFR 1560/4885SMN1; SMN2 2892/4885MTNR1A 301/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG EGFR 456/4885SMN1; SMN2 3475/4885MTNR1A 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.